Tsague Landry, Koulla Sinata S, Kenfak Alain, Kouanfack Charles, Tejiokem Mathurin, Abong Therese, Mbangue Madeleine, Mapoure Yacouba Njankouo, Essomba Claudine, Mosoko Jembia, Pouillot Regis, Menyeng Louis, Epee Helene, Tchuani Carno, Zoung-Kanyi Anne Cecile, Bella Lucienne Assumpta, Zekeng Leopold
Directorate for Disease Control, Ministry of Public Health, Cameroon;
Pan Afr Med J. 2008 Jul 4;1:2.
Retention in long-term antiretroviral therapy (ART) program remains a major challenge for effective management of HIV infected people in sub-Saharan Africa. Highly Active Antiretroviral Therapy (ART) discontinuation raises concerns about drug resistance and could negate much of the benefit sought by ART programs.
Based on existing patient records, we assessed determinants of retention in HIV care among HIV patients enrolled in an urban ART at two urban hospitals in Cameroon. Extended Cox regression procedures were used to identify significant predictors of retention in HIV care.
Of 455 patients, 314 (69%) were women, median (IQR) age and baseline CD4 cell count were respectively 36 years (30 - 43) and 110 cells/μL (39 - 177). Forty patients (9%) had active tuberculosis (TB) at enrollment. After a median (IQR) follow-up of 18 months (10-18), 346 (75%) were still in care, 8 (2%) were known dead, and 101 (22%) were lost to follow-up (LFU). Severe immunosuppression (CD4 cell count ≤ 50 cells/μL) at baseline (aHR 2.3; 95% CI 1.4 - 3.7) and active tuberculosis upon enrollment (aHR 1.8; 95% CI 1.0 - 3.6) were independent predictors of cohort losses to follow-up within the first 6 months after HAART initiation.
These data suggest that three-quarter of HIV patients initiated on HAART remained in care and on HAART by 18 months; however, those with compromised immunologic status at treatment initiation, and those co-infected with TB were at increased risk for being lost to follow-up within the first 6 months on treatment.
在撒哈拉以南非洲地区,长期坚持抗逆转录病毒治疗(ART)方案仍然是有效管理艾滋病毒感染者的一项重大挑战。停止高效抗逆转录病毒治疗(HAART)引发了对耐药性的担忧,并且可能会抵消ART方案所追求的大部分益处。
基于现有的患者记录,我们评估了喀麦隆两家城市医院中参加城市ART项目的艾滋病毒患者坚持接受艾滋病毒护理的决定因素。采用扩展的Cox回归程序来确定坚持接受艾滋病毒护理的显著预测因素。
在455名患者中,314名(69%)为女性,年龄中位数(四分位间距)和基线CD4细胞计数分别为36岁(30 - 43岁)和110个细胞/μL(39 - 177)。40名患者(9%)在入组时患有活动性结核病(TB)。在中位数(四分位间距)为18个月(10 - 18个月)的随访后,346名(75%)仍在接受护理,8名(2%)已知死亡,101名(22%)失访(LFU)。基线时严重免疫抑制(CD4细胞计数≤50个细胞/μL)(调整后风险比[aHR] 2.3;95%置信区间[CI] 1.4 - 3.7)以及入组时患有活动性结核病(aHR 1.8;95% CI 1.0 - 3.6)是HAART开始后前6个月队列失访的独立预测因素。
这些数据表明,开始接受HAART治疗的艾滋病毒患者中有四分之三在18个月时仍在接受护理并继续接受HAART治疗;然而,治疗开始时免疫状态受损的患者以及合并感染结核病的患者在治疗的前6个月内失访风险增加。